Recent Updates and Advances in Winiwarter-Buerger

diagnostics
Review
Recent Updates and Advances in Winiwarter-Buerger Disease
(Thromboangiitis Obliterans): Biomolecular Mechanisms,
Diagnostics and Clinical Consequences
Bahare Fazeli 1,2,† , Daniela Ligi 3,† , Shayan Keramat 4 , Rosanna Maniscalco 3 , Hiva Sharebiani 1
and Ferdinando Mannello 3, *
1 Immunology Research Center, Inflammation and Inflammatory Diseases Division, School of Medicine,
Mashhad University of Medical Science, Mashhad 9177948564, Iran; [email protected] (B.F.);
[email protected] (H.S.)
2 Vascular Independent Research and Education, European Organization, 20157 Milan, Italy
3 Unit of Clinical Biochemistry, Department of Biomolecular Sciences, Section of Biochemistry and Biotechnology,
University “Carlo Bo” of Urbino, 61029 Urbino, Italy; [email protected] (D.L.);
[email protected] (R.M.)
4 Hematology Department, Faculty of Medicine, Mashhad University of Medical Science, Mashhad 9177948564, Iran;
[email protected]
* Correspondence: [email protected]
† These authors contributed equally to this work.
Abstract: Thromboangiitis obliterans (TAO) or Buerger’s disease is a segmental inflammatory, throm-

botic occlusive peripheral vascular disease with unknown aetiology that usually involves the medium
Citation: Fazeli, B.; Ligi, D.; Keramat, and small-sized vessels of young male smokers. Due to its unknown aetiology and similarities with
S.; Maniscalco, R.; Sharebiani, H.; atherosclerosis and vasculitis, TAO diagnosis is still challenging. We aimed to review the status of
Mannello, F. Recent Updates and
biomolecular and laboratory para-clinical markers in TAO compared to atherosclerosis and vasculitis.
Advances in Winiwarter-Buerger
We reported that, although some biomarkers might be common in TAO, atherosclerosis, and vasculi-
Disease (Thromboangiitis Obliterans):
tis, each disease occurs through a different pathway and, to our knowledge, there is no specific and
Biomolecular Mechanisms,
definitive marker for differentiating TAO from atherosclerosis or vasculitis. Our review highlighted
Diagnostics and Clinical
Consequences. Diagnostics 2021, 11,
that pro-inflammatory and cell-mediated immunity cytokines, IL-33, HMGB1, neopterin, MMPs,
1736. https://doi.org/10.3390/ ICAM1, complement components, fibrinogen, oxidative stress, NO levels, eNOS polymorphism,
diagnostics11101736 adrenalin and noradrenalin, lead, cadmium, and homocysteine are common markers. Nitric oxide,
MPV, TLRs, MDA, ox-LDL, sST2, antioxidant system, autoantibodies, and type of infection are
Academic Editor: Paolo Zamboni differential markers, whereas platelet and leukocyte count, haemoglobin, lipid profile, CRP, ESR, FBS,
creatinine, d-dimer, hypercoagulation activity, as well as protein C and S are controversial markers.
Received: 16 July 2021 Finally, our study proposed diagnostic panels for laboratory differential diagnosis to be considered
Accepted: 14 August 2021 at first and in more advanced stages.
Published: 22 September 2021
Keywords: Buerger’s disease; Thromboangiitis obliterans; oxidative stress; antioxidant capacity;

Publisher’s Note: MDPI stays neutral
blood count; lipid profile; cytokines; autoantibodies; hypercoagulation; infection
with regard to jurisdictional claims in
published maps and institutional affil-
iations.
1. Introduction
Thromboangiitis obliterans (TAO) or Buerger’s disease is a segmental inflammatory,
thrombotic occlusive peripheral vascular disease with unknown aetiology that usually
Copyright: © 2021 by the authors.
involves the medium and small-sized vessels of young male smokers [1]. TAO has geo-
Licensee MDPI, Basel, Switzerland.
graphical distribution, and it is more common in the Middle East, Far East, South-East
This article is an open access article
distributed under the terms and
Asia, Eastern Europe, and South America [2]. However, there is still no explanation for the
conditions of the Creative Commons
geographic distribution of TAO.
Attribution (CC BY) license (https:// Due to the unknown aetiology of TAO, its diagnosis is still challenging. Pathology of
creativecommons.org/licenses/by/ the acute lesions is pathognomonic for TAO diagnosis [3]. However, the pathology study is
4.0/). possible on amputees. Even biopsies of superficial thrombophlebitis are not recommended
Diagnostics 2021, 11, 1736. https://doi.org/10.3390/diagnostics11101736 https://www.mdpi.com/journal/diagnostics

Diagnostics 2021, 11, 1736 2 of 20
in TAO patients due to the poor circulation of the limb and the risk of developing chronic
ulcers at the site of biopsy.
Moreover, until recently, TAO could neither be suggested nor be diagnosed according
to biological markers.
Therefore, several diagnostic criteria have been suggested for TAO diagnosis. In
particular, one of the most acceptable in the countries where TAO is common is Shionoya’s
clinical criteria [4]. These criteria refer to the clinical manifestation of the disease and
the absence of atherosclerotic risk factors except for smoking (e.g., hyperlipidemia and
diabetes). Since TAO is usually registered in low socioeconomic classes or countries
with social, economic, or political crises [5], Shionoya’s clinical criteria are eligible for
these patients to escape the considerable costs of imaging. However, Shionoya suggested
these criteria in 1988, whilst the cut-off points for the definition of hyperlipidemia and
diabetes in the 1980s were different from their current cut off points. Several biomarkers
of atherosclerosis have been introduced and studied during the last decades, and some
of them, like hyper-homocysteinemia, have been reported in both atherosclerosis and
TAO [6,7].
However, some angiologists prefer to diagnose TAO by excluding other types of
vasculitis and hypercoagulable states based on laboratory para-clinical findings alongside
the imaging [8].
In this paper, we will review the status of studied biomolecular and laboratory para-
clinical markers in TAO compared to atherosclerosis, vasculitis, and hypercoagulopathies.
2. Complete Blood Count (CBC)

Several studies reported anaemia, most commonly normochromic and normocytic
type, in about 40% of TAO patients, particularly during the acute exacerbation of the
disease [9,10]. Notably, a significant inverse correlation between haemoglobin (Hb) level
and duration of smoking has been reported in TAO patients, which is not anticipated
because a high Hb level would be expected in long-term, heavy smokers [9]. Moreover,
one of these studies demonstrated that Hb from TAO patients had decreased over a short
period of time, with a trend that did not resemble trends found in chronic anaemia, as
observed in other types of vasculitis [9].
In another study, although the indirect Coombs test was positive in 70% of the TAO
patients with high levels of LDH (Lactate dehydrogenase) and AST (Aspartate aminotrans-
ferase) and normal levels of ALT (Alanine aminotransferase), the definitive diagnosis of
hemolytic anaemia was not confirmed, because of the normal level of bilirubin as well as
the normal or high level of haptoglobin [10].
Although normal platelet count has been reported in TAO patients, thrombocytosis
and thrombocytopenia have been reported in 6.4% and 2.9% of the patients, respectively [9].
Notably, thrombocytosis has been observed in those patients who underwent major ampu-
tation. Leukocytosis and neutrophilia have also been reported in TAO patients during the
acute exacerbation of the disease [9].
Notably, leukocytosis, thrombocytosis, and normochromic and normocytic anaemia
are usually seen in systemic vasculitis [11,12]. Moreover, leukopenia and thrombocytopenia
are more common in vasculitis, whilst anaemia is also observed in systemic vasculitis.
Increased platelet response to serotonin has been described in TAO patients compared
to healthy male controls. About half of the controls in this study were smokers [13].
In contrast to atherosclerosis or vasculitis, low mean platelet volume (MPV) has been
observed in TAO patients [14]. MPV is an indicator of platelet activation, and there is
strong evidence indicating that MPV is an important variable and that larger platelets
have a higher thrombogenicity. It is implicated that the severe inflammatory condition
has been associated with low MPV, which increases with anti-inflammatory therapy [14].
Interestingly, it has been reported that other metabolic disorders, such as high cholesterol
and diabetes, have an association with increased MPV, and this could indicate a link
between increased MPV and atherosclerosis [15].
Diagnostics 2021, 11, 1736 3 of 20
The disease activity and severity in some vasculitis, such as Behcet’s disease, has been
associated with higher MPV [16], and in some other vasculitis, such as Systemic Lupus
Erythematous (SLE), has been associated with lower MPV [17].
A summary of the main findings is reported in Table 1.
Table 1. Summary of the main findings on Complete Blood Count (CBC).
CBC TAO Atherosclerosis Vasculitis

Anaemia Has been reported Independent factor Common
Mostly normal;
rarely high in patients
with major
Thrombocytopenia is
Platelet count amputation or low Normal
common
due to consumption
in thrombosis
formation
Leukocytosis with Mostly high and
Leukopenia is
Leukocyte count neutrophilia has been considered as a risk
common
reported factor
Mostly high due to
MPV Mostly low Mostly normal
hyperactivation
3. Biochemical Markers
3.1. Lipid Profile
For years, TAO had been misunderstood as a kind of presenile atherosclerosis oblit-
erans [18,19]. However, after the recognition of TAO as an individual disease, excluding
the risk factors of atherosclerosis (e.g., diabetes and hyperlipidemia) became a part of the
diagnostic criteria of TAO [4].
Notably, it seems that long term smoking influences the lipid profile, with higher
cholesterol, higher low-density lipoprotein (LDL), and lower high-density lipoprotein
(HDL) [20].
The serum cholesterol level in TAO patients has been reported ranging from 157 mg/dL
to 225 mg/dL, whereas LDL and HDL levels were 94–112 mg/dL and 34–54 mg/dL, re-
spectively [21–23].
In 2013, Hus et al. reported significantly higher cholesterol serum levels in cigarette-
smoking TAO patients compared with non-smoking ones. However, regarding the serum
level of cholesterol in these patients, it has not been reported whether it was in the normal
range [21].
It is still unknown whether a low level of total cholesterol in TAO patients is due to any
impairment in mitochondria function or because of the bias of excluding hyperlipidemic
patients from TAO diagnosis.
3.2. Blood Sugar

During the 1930s, it was noticed that patients with TAO diagnosis did not have
diabetes [24,25]. Nowadays, hyperlipidemia and diabetes are also known as excluding
factors for a TAO diagnosis [4]. Even if a patient with a TAO diagnosis develops diabetes
years after the initial diagnosis of TAO, the TAO diagnosis would be ruled out retroactively.
In 1992, Papa et al. suggested not to rule out the initial diagnosis of TAO according to
typical clinical manifestation and angiography if the patient develops diabetes years after
TAO diagnosis [26].
In addition, a few cases of diabetes in patients with TAO diagnosis, confirmed by
pathology without any atherosclerotic plaque, have been reported. Notably, the patients’
fast blood sugar (FBS) was not more than 113 mg/dL [21,27,28].
According to pathological studies of below-knee amputees of two diabetic cases with
a diagnosis of PAD (peripheral artery disease), it has been reported that the diagnosis
Diagnostics 2021, 11, 1736 4 of 20
was TAO because of inflammatory thrombosis and the absence of atherosclerotic plaques.
However, they had excluded those cases from the TAO group because of their being
diabetic [22,29].
3.3. Oxidative Stress

Several studies indicate that oxidative stress promotes endothelial cell dysfunction
and can directly influence vascular tone by decreasing nitric oxide (NO) bioavailability [30].
This condition activates a vicious circle because a malfunctioned vascular endothelium is a
source of oxidative stress by itself. Moreover, besides vascular endothelium, it has been
demonstrated that vascular adventitia is a major producer of oxidative stress, particularly in
response to hypoxic stresses, where it has a key role in regulating vascular tone by targeting
NO bioavailability [31]. It seems that the known risk factors of cardiovascular disease,
including smoking, diabetes, and hyperlipidemia, lead to higher oxidative stress [32,33].
Notably, oxidative stress seems significantly higher in TAO patients than smoking
habit-matched controls [34]. This means that other factors besides smoking are responsible
for high oxidative stress in TAO patients. A low serum level of NO metabolites in TAO has
been reported compared to smoking controls, which might be one reason for high oxidative
stress in TAO. Nevertheless, it is not well defined if the low NO level is responsible for
high oxidative stress in TAO or secondary to high oxidative stress [35]. Moreover, it has
been reported that polymorphisms in the promoter region of nitric oxide synthase correlate
with major amputation in TAO patients [36]. Interestingly, besides NO alterations in TAO
patients, it has been demonstrated that the level of heme-oxygenase 1 (HMOX1), which is
implicated in maintaining the backup of nitric oxide, is intact and significantly higher in
TAO patients compared to controls [37].
Notably, a higher level of nitric oxide has been demonstrated in patients with coro-
nary artery disease [38]. Moreover, increased NO production has been reported in some
autoimmune conditions, including rheumatoid arthritis, systemic lupus erythematosus,
and Behcet’s disease [39–42].
oxLDL, malondialdehyde (MDA), carbonyl protein (PC), superoxide dismutase (SOD),
glutathione reductase (GR), myeloperoxidase (MPO), and coenzyme Q10 (co-Q10) are also
important markers that play a role in oxidative stress status [43–45]. Interestingly, in 2010,
Arslan et al. found that oxLDL was higher in patients with TAO than atherosclerosis [46].
Recently, a significantly lower level of MDA and SOD has been reported in TAO
patients compared to smoker controls [35]. Notably, a higher level of MDA and SOD has
been reported in atherosclerosis [33]. A higher level of MDA in SLE without any significant
association with the disease activity has also been reported [47]. However, SOD activity has
been reported as normal to significantly lower in SLE patients compared to controls [47,48].
No significant difference between PC, GR, and MPO levels has been demonstrated in
TAO vs. controls [35]. However, a higher level of PC has been reported in both atheroscle-
rosis and SLE [49,50].
Moreover, a higher level of glutathione reductase in atherosclerosis has been demon-
strated, whilst no significant difference in GR level has been reported in SLE [51,52].
Further, a higher level of MPO in atherosclerosis and the active phase of several
vasculitis, including Behcet’s disease has been reported [53,54].
Interestingly, the serum level of CoQ10 has been reported to be significantly higher in
TAO compared to controls. The high levels of CoQ10 in TAO patients might be responsible
for a lower level of MDA by increasing its catabolism [35]. Lower levels of CoQ10 have
been noticed in atherosclerosis and in some autoimmune diseases [55,56].
3.4. Creatinine
Elevated serum creatinine concentration was proposed to be a marker for increased
risk of cardiovascular disease mortality [57]. There are a few case reports about the
involvement of renal arteries in TAO and consequently higher creatinine level [58]. Serum
Diagnostics 2021, 11, 1736 5 of 20
creatinine level in systemic vasculitis could also be high according to the involvement of
the kidneys [59].
3.5. Catecholamine Concentration

Few studies have been performed to evaluate the level of catecholamines in TAO
patients, either in group studies or in case reports. They showed that the level of cate-
cholamines in patients with TAO increases. Of course, the effect of smoking on increasing
levels of catecholamines has also been clearly shown, but Roncon-Albuquerque et al.
demonstrated that in patients with TAO, cigarette smoking had different effects in plasma
catecholamines compared to controls [27,60]. According to their results, smoking decreased
noradrenalin in controls but increased in TAO patients. Although in TAO patients with sym-
pathectomy smoking did not significantly change noradrenalin, there was a pronounced
fall in adrenalin [60].
Compared with TAO, increased levels of catecholamines have also been reported in
patients with atherosclerosis. Bauch et al. have shown significantly high plasma concentra-
tions of epinephrine and norepinephrine in patients with coronary artery disease (CAD),
and they considered these results as a hypothesis revealing that catecholamines may play a
role in the development and subsequent complications of atherosclerosis [61]. In vasculitis,
the association of catecholamines with the disease has been clearly investigated, and the
results have led to the development of a group of vasculitis called Catecholamine-induced
vasculitis. Catecholamine-induced vasculitis is well known. Sarathi et al. [62], studying the
relationship between catecholamines and vasculitis, found a correlation between pheochro-
mocytoma and aortoarteritis, and thus demonstrated the essential role of catecholamines in
the development of aortoarteritis. This aspect has been recently confirmed by Toutai et al.,
who stated that high catecholamine levels may have a role in the etiopathogenesis of
aortoarteritis in these patients [63].
3.6. Heavy Metals

Food, smoking, and air pollution are the major sources of lead, cadmium, and other
toxic heavy metals such as arsenic [64]. Although the cardiovascular consequences of metal
toxicity have not been published widely enough, it has been demonstrated that heavy
metals induce vascular dysfunction by inducing high oxidative stress, reducing endothelial
nitric oxide synthase activities, and enhancing the phosphorylation of myosin light chain
kinases [65].
Various studies indicated that heavy metals in tobacco and other sources might be one
of the causative factors for TAO development. This is particularly true for cadmium, lead,
and arsenic [66].
An association between lead and cardiovascular disease has been recognized and
considered an established risk factor for oxidative stress, inflammation, and the triggering
event of atherosclerosis [67].
Moreover, the role of cadmium as a cardiovascular disease risk factor, especially for
coronary disease, has been indicated [68]. In addition, the role of heavy metals in the
formation of vasculitis has been reported [69]. Albert et al., studying Wegener’s granulo-
matosis (WG), found that mercury and lead have been associated with the etiopathogenesis
of WG [70]. On the other hand, it has been discussed that lead and its possible pro-
inflammatory action, including the influence on pro-inflammatory cytokine production
and its effective role in causing vasculitis, can be considered [71].
3.7. Bilirubin
Generally, abnormal bilirubin levels are considered a sign of hepatic disorders. Al-
though bilirubin has long been believed to be an excretory metabolite, one of the most
critical studies on the association between bilirubin and cardiovascular system pointed to
the effective role of bilirubin in preventing atherosclerosis [72]. In 1994, Schwertner et al.
found that lower bilirubin levels were significantly associated with an increased risk of coro-
Diagnostics 2021, 11, 1736 6 of 20
nary artery disease [73]. On the other hand, it was observed that increasing bilirubin levels
in cardiovascular patients are associated with a decreased risk of atherosclerosis [72–74]. In
TAO, bilirubin has been reported in normal range [10]. In vasculitis, especially autoimmune
vasculitis, the bilirubin can increase under the influence of autoimmune hemolytic anaemia
(AIHA) [75,76].
Tovoli et al. also observed the increase of bilirubin due to autoimmune liver disorders
(AILD) in small-vessel vasculitis [77]. Nevertheless, bilirubin plays an essential role in other
vasculitis as a diagnostic marker, such as Behcet’s disease, where a decrease in bilirubin
can be observed, according to Koca et al. [78].
3.8. Liver Function Test

The evaluation of liver function tests (LFT) provides many indications and is mainly
performed in systemic diseases as a prognostic indicator. Notably, the patient’s age can
influence the results of AST as a positive correlation and ALT as a negative correlation [79].
Higher levels of AST and normal levels of ALT have been reported in young TAO
patients [75].
However, a higher level of ALT, as a marker of fatty liver and increasing the risk of
insulin resistance, seems a risk factor for atherosclerosis [80].
Moreover, higher levels of liver enzymes have been noticed in several autoimmuni-
ties [77].
Table 2. Summary of the main findings on biochemical markers.
Biochemical Markers TAO Atherosclerosis Vasculitis

Normal to slightly high
Fast Blood Sugar Normal to high Normal
(< 120 mg/dL)
Cholesterol Normal to slightly high High Normal
LDL Normal to slightly high High Normal
HDL Low to normal Low Normal
High with intact antioxidant High with impaired High in several autoimmune
Total oxidative stress
capacity antioxidant capacity vasculitis
MDA Normal High High
Low with eNOS
Low with eNOS polymorphism
NO High
polymorphism High in SLE and RA with
iNOS high expression
Slightly high in
Anca-Associated Vasculitis
Creatinine High Normal to slightly high
(AAV) and normal in Behcet’s
disease
High level of lead and is
High level of lead, cadmium,
Heavy metals High level of lead, cadmium related to mercury in
arsenic
Wegener’s granulomatosis
High especially in
High level of adrenalin and High level of epinephrine and
Catecholamine concentration catecholamine-induced
noradrenalin norepinephrine
vasculitis
Low to High High in AILD with small
Bilirubin Normal High levels associated with vessel vasculitisLow in
good prognosis Behcet’s disease
High in liver involvement
Hepatic function test Mostly high level is related to
High AST with normal ALT related to AAV and
(AST and ALT) fatty liver
Rheumatoid Arthritis
Diagnostics 2021, 11, 1736 7 of 20
4. Inflammatory Biomarkers
4.1. C-Reactive Protein and Erythrocyte Sedimentation Rate
C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) have been usually
observed in normal range in TAO patients [30]. Moreover, in some TAO diagnostic criteria,
positive ESR and CRP have been considered factors for ruling out TAO diagnosis [81].
However, several studies reported high levels of CRP in TAO patients [75,82]. There is no
study on ESR levels in TAO patients.
4.2. Cytokines
Although TAO is not known as systemic vasculitis, the serum levels of different
cytokines have been evaluated in TAO patients. Significantly higher serum levels of pro-
inflammatory cytokines, including TNF-alpha (TNF-α), interleukin-1 beta (IL-1β), and
interleukin-6 (IL-6), have been reported in TAO patients compared to controls [83,84].
Nevertheless, in the work of Joras et al., the serum level of TNF-α had no significant
difference between TAO and controls [85]. Moreover, cytokines of cellular immunity,
including interferon-gamma (IFN-γ) and interleukin 12 (IL-12), cytokines of humoral
immunity including interleukin 4 (IL-4), interleukin 5 (IL-5), and interleukin 13 (IL-13),
have been reported in TAO patients compared to smoker controls [83].
Moreover, high serum levels of IL-17, -22, -23, and -33 and low IL-10 have been
reported in TAO compared to smoker controls [14,86,87].
The levels of cytokine released and the T-cell mediated immunity in TAO could also
be the result of different HLA patterns of expression in TAO patients, as reported by
Shapouri-Moghaddam et al. [88].
4.3. Complement Component

High levels of C4 have been reported in patients with a severe form of TAO [89].
Notably, a high serum level of C3 and C4 has also been reported in atherosclerosis [89].
However, serum levels of C3 and C4 range from low to high according to the type of
vasculitis [90,91].
4.4. Other Inflammatory Mediators

As a biomarker of cellular immunity, Neopterin has been reported to be significantly
higher in the active phase of TAO compared to its quiescent phase and controls [92].
Toll-like receptors (TLRs) are the main components of innate immunity and have an
essential role in the pathogenesis of autoimmune and autoinflammatory diseases. Notably,
TLR4 has been reported to be significantly lower in the quiescent phase of TAO compared
to controls. In patients with active TAO, no difference between the serum level of TLR4 in
patients and controls has been found. No changes in serum levels of TLR2 in active and
quiescent phase of TAO or between TAO patients and controls have been found [92].
High mobility group box 1 protein (HMGB1), which acts as a pro-inflammatory
cytokine, has been reported to be significantly higher in TAO patients than healthy non-
smokers [93]. Moreover, significantly increased intercellular adhesion molecule -1 (ICAM-1)
and vascular cell adhesion molecule -1 (VCAM-1), key regulators of vascular permeability,
have been demonstrated in TAO patients compared to healthy non-smokers [94,95].
Notably, a significantly high level of matrix metalloproteinase 9 (MMP-9) as a regulator
of vascular permeability in TAO patients compared to non-smokers has been reported [93].
Similarly, high levels of different classes of MMPs have been reported in atherosclerosis
and vasculitis [96–98].
Diagnostics 2021, 11, 1736 8 of 20
Table 3. Summary of the main findings on inflammatory markers.
Inflammatory Biomarkers TAO Atherosclerosis Vasculitis

High (usually >18 and Extremely high
ESR Controversial
<30 mm/h) (even >100 mm/h)
High (usually 5 to 15 mg/L)
More than 25 mg/L as a
CRP Controversial High (usually >12 mg/L)
marker of infection in
vasculitis
Pro-inflammatory High level of TNF-α, IL-1,IL-6 High level of IL-1, IL-6, IL-18 High level of TNF-α, IL-1,IL-6
Th1-related High level of IL-12 IFN-γ High level of IL-12 High level of IFN-γ, IL-12,
Th2-related High level of IL-4, IL-5, IL-13 High level of IL-4, IL-5 High level of IL-4, IL-5, IL-13
High level of IL-17, IL-22, High level of IL-21, IL-22, High level of IL-23, IL-17,
Th17-related
IL-23, IL-21 IL-23 IL-21
Anti-inflammatory Low level of IL-10 Low levels of TGF-β, IL-10 High level of IL-10
High level of IL-33 (without
increasing levels of Soluble High level of IL-35, IL-33, High level of IL-33 (with
Others
suppression of IL-15 increased sST2 level)
tumorigenicity-2, sST2)
HMGB1 High High High
Neopterin High in the acute phase High High
TLRs Low level of TLR4 High level of TLR4 and TLR2 High level of TLR4 and TLR5
High MMP-1, MMP-2,
Matrix Metalloproteinases
High MMP-9 MMP-9, MMP-3, MMP-12, High MMP-2, MMP-9, MMP-3
(MMPs)
MMP-13
ICAM1 High High High in AAV, SLE, WG
High C3, C4 levels in immune
High level of C4 in patients complex-mediated vasculitis
Complement component High serum level of C3, C4
with severe form of TAO are reported while in SLE, C3
and C4 were decreased
5. Autoantibodies
Until recently, TAO is not known as a systemic vasculitis, and it is still unknown
whether it is an autoimmune disorder [86,87]. However, the existence of several autoanti-
bodies in some TAO patients has been reported, including anti-endothelial cell antibody
(AECA), anti-elastin, and anti-collagen I and III antibodies [99–102]. In 1998, the presence
of antineutrophil cytoplasmic antibodies (ANCA) was reported in patients with TAO [103].
The study found a significantly higher ANCA level in patients with severe clinical man-
ifestations compared to patients with mild disease and controls [104]. However, several
further studies have ruled out the presence of ANCA in TAO patients and their association
with the disease [105].
In addition, high levels of anti-cardiolipin antibody and anti-Beta2 glycoprotein an-
tibody have been reported in TAO patients [106]. Due to the fluctuation in the levels of
these antibodies, the diagnosis of anti-phospholipid syndrome could not be established.
However, it seems that TAO patients with high anti-cardiolipin titers tend to be younger
and to suffer from a significantly higher rate of major amputations [106].
As reported in Table 4, some autoantibodies have also been described in vasculitis
and atherosclerosis [107–110].
Diagnostics 2021, 11, 1736 9 of 20
Table 4. Summary of the main findings on autoantibodies.
Autoantibodies TAO Atherosclerosis Vasculitis

Anti-Cardiolipin positive (IgM class) Negative positive (mostly IgG class)
Anti-dsDNA, ANA Negative Negative Positive in vasculitis such as SLE
Anti-beta2 positive (IgM class) positive (IgM class) Not reported
AECA positive Negative positive
ANCA negative Negative Positive in AAV
Lupus anticoagulant negative Negative positive
6. Thrombogenicity
Hypercoagulation
Although hypercoagulability has been considered an exclusive factor for TAO diagno-
sis, several studies have reported thrombogenic risk factors in TAO patients.
For instance, lower clot permeability and prolonged clot lysis time in TAO patients
compared to other types of peripheral arterial diseases (PADs) and smoker controls have
been reported [111].
Also, increased thrombin formation has been reported in TAO patients [112]. Although
a significantly higher level of urokinase-plasminogen activator (uPA) and lower level of
plasminogen activator inhibitor I (PAI-1) have been reported in TAO, fibrinolysis seems to
be impaired [21,113]. However, another study reported that PAI-1 was expressed along the
internal elastic lamina, whereas urokinase-type plasminogen activator and MMP-3 were
slightly expressed in intima and media [114].
Interestingly, it seems that D-dimer released from clots is markedly slower in TAO
patients compared to other patients with PADs [111,115].
A significantly higher level of fibrinogen in TAO patients compared to patients with
other types of PADs or healthy smokers has been reported [111,113].
Protein C and S deficiency has been considered as exclusive factors for TAO diag-
nosis [115]. However, two separate case reports have implied the co-existence of Protein
C and S deficiency with TAO [116]. Moreover, a mutation in factor Leiden V has been
reported in TAO patients via a few case reports. Interestingly, almost all of these case
reports have thrombosis in large vessels or deep venous thrombosis, but the histopathology
of the amputees was suggestive for TAO [117,118].
Hyperhomocysteinemia has also been reported in TAO patients [119]. Hyperhomocys-
teinemia can induce thrombogenicity by increasing vascular adhesion molecules and tissue
factors, inhibiting fibrinolysis as well as inducing nitric oxide bioavailability impairment
and platelet activation [120]. Nevertheless, its level in TAO patients compared to healthy
smokers is controversial in different studies. Some studies have considered hyperhomocys-
teinemia as an independent risk factor for TAO development. However, in other studies,
due to the absence of significant differences between homocysteine levels in TAO patients
and healthy smokers, hyperhomocysteinemia as a consequence of smoking in TAO patients
was not considered an individual risk factor [120,121]. On the contrary, in atherosclerosis,
it has been described a normal coagulation profile [122].
On the other hand, in vasculitis, a hypercoagulable profile has been reported in both
Behçet syndrome and AAV, in which the main cause is referred to NETosis and endothelial
dysfunction, respectively [123]. Furthermore, high levels of d-dimer have been often
reported in AAV, SLE, granulomatosis with polyangiitis (GPA), Henoch-Schönlein purpura,
and Kawasaki disease [124].
Finally, increased levels of homocysteine have also been reported in atherosclerosis
and vasculitis [125,126].
Diagnostics 2021, 11, 1736 10 of 20
Table 5. Summary of the main findings on thrombotic factors.
Thrombotic Factors TAO Atherosclerosis Vasculitis

Mostly considered as normal, Hypercoagulable states
Hypercoagulation activity but with increased risk with Normal activity mostly reported in Behçet
Factor V Leiden mutation syndrome and AAV
High levels in AAV, SLE,
It has been reported D-dimer Granulomatosis with
d-dimer levels are considerably High in thrombotic event polyangiitis (GPA)
elevated in patients with TAO Henoch-Schönlein purpura,
Kawasaki disease
Fibrinogen level High level High High in systemic vasculitis
Protein C and Protein S
deficiency has been reported
Protein C, Protein s Mostly considered as normal Normal
as a risk factor for aggravation
of atherosclerosis
Hyperhomocysteinemia Has been reported Has been reported Has been reported
7. Infection
The footprint of infectious pathogens in TAO development was suggested early after
the disease description by Leo Buerger [127,128]. However, until recently, two pathogens
attracted the attention: oral bacteria and rickettsial infection. Although the high im-
munoglobulin titer against oral bacteria and rickettsia has been reported, it is not evaluated
in the routine practice for TAO diagnosis [129,130].
A summary of the main findings herein described is reported in Table 6.
Table 6. Summary of the main findings on infection.
TAO Atherosclerosis Vasculitis

Viral infection (e.g., Human
Chlamydophila pneumoniae,
Immunodeficiency Virus and CMV),
Oral bacteria and rickettsial Helicobacter pylori, CMV
Infection Streptococcus pneumoniae, rickettsia,
infection. (Cytomegalovirus) and oral
Mycobacterium, Staphylococcus
bacteria
aureus, Chlamydia, Neisseria
8. Genetic Background
Several studies have been conducted on the genetic background of TAO. Although
susceptibility to TAO has been suggested to be at least in part controlled by genes involved
in innate and adaptive immunity, vascular physiology, platelet function or coagulation
pathways, the presence of any particular gene polymorphism is controversial.
One of the most critical limitations of studies on genetic background of TAO is the lack
of sufficient sample size due to the rarity of the disease. Obviously, allele frequencies based
on small sample sizes will increase the false-positive evidence for linkage [131]. Besides,
there is a lack of supporting studies regarding any polymorphism claim for TAO. These
limitations make the results of genetic studies on TAO not quite reliable. For instance,
several studies have explored HLA typing in TAO since the 1990s [88,132–136]. Although
few polymorphisms have been detected to be associated with TAO in each study, the results
are quite regional. Besides HLA-DRB1*15, which is a common polymorphism in TAO
patients from Iran and India [88,135], and HLA-DRB1*04, which is a common polymor-
phism in the TAO patients from Japan and Iran [88,136], the rest of the polymorphisms
of HLAs in TAO patients have been varied in different regions. Notably, HLA-DRB1*15
has also been reported as a risk factor for PR3-ANCA associated vasculitis in African
Americans [137], and HLA-DRB1*04 has been associated with several vasculitis [138–140].
Diagnostics 2021, 11, 1736 11 of 20
No association between HLA-DRB1*15 and atherosclerosis has been reported. However,

early cardiovascular events in smokers with HLA-DRB1*04 have been noticed [141].
Besides HLA typing, several studies on the single nucleotide polymorphism of nitric
oxide synthase, endothelin 1, plasminogen activator inhibitor, platelet receptors, homocys-
teine, Factor V, prothrombin, and Toll-like receptor 4 and CD14 have been conducted on
TAO patients.
However, until recently, among all studied polymorphisms, only two studies had
reported the association of eNOS T-786 C polymorphism of endothelial nitric oxide synthase
with TAO [36,142]. Interestingly, according to a meta-analysis conducted in 2015, there was
no association between eNOS T-786 C polymorphism and vasculitis [143]. However, the
association between eNOS T-786C and atherosclerosis seems to be controversial [144,145].
9. Discussion
Until recently, the aetiology and even TAO classification as a kind of PAD or small
and medium-sized vasculitis has remained challenging.
Notably, during the 1960s, after reporting TAO cases with visceral involvement as
well as evidence of atherosclerotic lesions in visceral vessels from the autopsy of some
TAO cases, TAO was considered as a type of atherosclerosis obliterans (ASO) with slow
collateralization of the lesions and also the retrograde extension of the lesions from distal
to proximal in comparison with usual cases of ASO. However, later, according to several
studies on large series of TAO patients, the clinicopathological findings and angiography
manifestation were considered characteristic for TAO as a separate disease from ASO or
vasculitis [1].
Maybe, when we consider a young smoker with thrombophlebitis migrans and vas-
cular involvement of infrapopliteal arteries and upper limbs, with normal blood sugar,
normal lipid profile, and normal blood pressure, with typical skip lesions and corkscrew
collaterals in angiography, the TAO diagnosis seems to be easy. However, there are sev-
eral cases where the disease manifestation might be after 45 years, the patient might not
be smoker, have dyslipidemia or glucose intolerance, or even high blood pressure with-
out any atherosclerotic plaque, but at the same time present without obvious corkscrew
collaterals [27,28]. Hence, the diagnosis of such cases as TAO would not be easy.
Up to now, TAO diagnosis is based on ruling out ASO and other types of vasculitis [4].
Usually, such investigations are not pathological studies only because tissue sampling on
ischemic limbs are not practical. Therefore, biomarkers are usually investigated for ruling
out ASO and other types of vasculitis.
However, inflammation, thrombosis, infection, and the presence of some autoantibod-
ies are a part of the pathophysiology of TAO, ASO, and vasculitis and could be detected
in patients with any of these diagnoses. Hence, for challenging cases like TAO clinical
manifestation in older patients or non-smoker patients, these biomarkers might not be
helpful but also making the diagnosis more complicated.
Although some biomarkers might be common in ASO, TAO, and vasculitis, each
disease occurs through a different pathway with different origins. On the other hand,
according to our current knowledge, there is no specific and definitive marker for differen-
tiating TAO from atherosclerosis or vasculitis [9]. Hence, the mechanistic investigation of
biomarkers is more useful and applicable.
Mechanistic investigations are a kind of fuzzy logic that demonstrate the concept
of partial truth, where the truth value may range between completely true (one) and
completely false (zero).
Based on this approach, there are three groups of markers: (1) similar markers, (2) con-
troversial markers, (3) and differential markers.
9.1. Similar Biomarkers

Pro-inflammatory and cell-mediated immunity (CMI) cytokines, IL-33, HMGB1,
neopterin, MMPs, ICAM1, complement components, fibrinogen, oxidative stress, NO
Diagnostics 2021, 11, 1736 12 of 20
levels, eNOS polymorphism, adrenalin and noradrenalin, lead, cadmium, and homocys-
teine are the common markers.
Thrombosis, inflammation, presence of autoantibodies, endothelial injury or dys-
function, vasoconstriction, high oxidative stress, and infection are common pathological
pathways in these diseases. Similar markers are derived from these common pathways.
For example, NO level is associated with vasoconstriction [146], pro-inflammatory and cell-
mediated immunity (CMI) cytokines, HMGB1, IL-33, neopterin, ICAM1, and complement
components are most related to inflammation and infection [147–149]. Lead, cadmium, ox-
idative stress, and MMPs are related to cell damage [64,93]. Fibrinogen and homocysteine
can be related to thrombosis [111,119].
9.2. Controversial Biomarkers

The controversial markers are platelet and leukocyte count, haemoglobin, lipid profile,
CRP, ESR, FBS, creatinine, d-dimer, hypercoagulation activity, protein C, and S. Many fac-
tors including family history and genetics, underlying medical conditions, environmental
conditions, consumption of some drugs, and accompanying other diseases have effects on
the levels of these markers. Therefore, these factors should be considered along with these
conditions and the complete history of patients.
For example, although most TAO patients have normal FBS and do not have diabetes,
they can still have these two conditions simultaneously. It has been reported that some
clinicians rule out the several years’ diagnosis of TAO because of high levels of FBS that
recently occurred [26]. Even if the mechanism of disease decreases blood sugar and
lipids, the basic levels of these molecules are different in each patient, depending on
their genetic and history. Therefore, we see different levels of FBS and lipid profile in
these patients [20–23,27,28]. These differences should not cause the early rule out of TAO
diagnosis. In these cases, we should consider the whole data of each patient, including
their signs and symptoms, pathology results, angiography, and other biomarker test results.
For example, in the case of lipid profile, evaluation of TLR4 level, ox-LDL, and MDA can
be helpful for the differentiation of TAO and atherosclerosis [35,92,93].
Infection, some drugs, and underlying conditions can have effects on platelet and
leukocyte count [150]. Therefore, all of these conditions should be considered case by case,
personally.
Anaemia is one of the most controversial conditions in these diseases. Smoking can
induce high levels of haemoglobin in smokers. However, in TAO patients, several cases
of anaemia have been reported, and notably, the haemoglobin level is associated with the
prognosis of TAO patients [10]. In atherosclerosis patients, anaemia is an independent
risk factor for CVD outcomes [151]. In vasculitis, anaemia is a common condition that
is more related to ANCA associated vasculitis (AAV) [152]. Therefore, it seems that the
pathogenetic mechanisms of TAO and vasculitis can cause anaemia, while in atherosclerosis,
anaemia is just an independent risk factor for CVD. These findings show that the underlying
conditions unrelated to atherosclerosis are probably responsible for causing anaemia in
atherosclerosis patients. Meanwhile, in TAO and vasculitis, anaemia should be considered
in the context of these diseases as a part of them [9].
Different triggers, such as infection, inflammation pathways, and autoimmune re-
sponses, can induce elevated levels of CRP and ESR. These triggers usually are common in
these three diseases, despite the origin, type, and pathway of them being specific in each
disease. However, CRP and ESR do not have enough specificity for each pathway and are
elevated in all of them, so we cannot recognize which one was responsible. Furthermore,
some pain killers like NSAIDs (nonsteroidal anti-inflammatory drugs), usually taken by
TAO patients, can influence the result of ESR [153].
In atherosclerosis, thrombosis is a consequence and product of the disease and happens
suddenly as an event. Whilst in TAO and vasculitis, this is a part of pathogenesis and
occurs consistently. As a marker that indicates the thrombosis and fibrinolysis situation,
Diagnostics 2021, 11, 1736 13 of 20
D-dimer has an elevated level in TAO and vasculitis consistently, while in atherosclerosis it
rises during a thrombotic event [111].
9.3. Differential Biomarkers

Nitric oxide, MPV, TLRs, MDA, ox-LDL, sST2, antioxidant system, autoantibodies,
and type of infection are differential markers.
Numerous studies show that although the diagnosis of TAO is ambiguous, despite
the similarities, there are still significant differences between TAO, atherosclerosis, and
vasculitis among laboratory markers that could be routinely effective in the differential
diagnosis of TAO. Therefore, by examining these differences more closely, it is possible
to design differential diagnostic panels and differentiate the TAO from atherosclerosis
and vasculitis from the beginning of the patient’s visit to the laboratory with the simplest,
routine, and, of course, cheapest tests.
In general, our studies show that, for laboratory differential diagnosis between TAO
and atherosclerosis or vasculitis, tests, such as CBC, Cholesterol, HDL and LDL, FBS, ANA,
Anti-dsDNA, and Lupus anticoagulant, should be considered first. Then, in more advanced
stages after the initial tests, more detailed diagnostic charts can be designed. In these charts,
Anti-Cardiolipin (IgM class), Anti-beta2 (IgM class), ANCA, oral bacteria and rickettsia,
oxLDL, and other mediators such as TLR4 can be tested. Evaluating ESR, CRP, or protein
C and S is not recommended as diagnostic biomarkers for TAO (Tables 7 and 8).
Table 7. Routine laboratory differential diagnostic tests for TAO and Atherosclerosis.
Disease
TAO Atherosclerosis
Biomarker
Cholesterol Normal to slightly high High
LDL Normal to slightly high High
HDL Low to Normal Low
FBS Normal to slightly high Normal to high (in diabetic patients)
Anti-Cardiolipin Positive (IgM class) Negative
Protc, prots Normal Prot c and prot s deficiency
MPV mostly Low mostly High
oxLDL Normal High
Oral bacteria and rickettsial infection. Positive Negative for rickettsial infection
TLR-2 and -4 Low level of TLR4 High level of TLR4 and TLR2
Diagnostics 2021, 11, 1736 14 of 20
Table 8. Routine laboratory differential diagnostic tests for TAO and Vasculitis.
Disease
TAO Vasculitis
Biomarker
ESR Controversial High
CRP Controversial High
Anti-dsDNA, ANA Negative Positive
Lupus anticoagulant Negative Positive
Anti-Cardiolipin Positive Positive
Anti-beta2 Positive Not reported
ANCA Negative Positive
Oral bacteria and rickettsial infection. Positive Positive for rickettsial infection
Mostly considered as normal but hypercoagulable states mostly
Hypercoagulation activity with increased risk with Factor V reported in Behçet syndrome and
Leiden mutation AAV
Mostly normal;
Platelet count (rarely high or low in specific thrombocytopenia
conditions)
Leukocyte count Leukocytosis with neutrophilia Leukopenia
TLR Low level of TLR4 High level of TLR4 and TLR5
10. Conclusions
Unfortunately, even after more than a century since Buerger first defined TAO, its
diagnosis continues to be challenged. To date, no definitive biomarker points to a TAO
diagnosis in patients with unusual manifestations of the disease or in patients with the risk
factors of atherosclerosis or autoantibodies.
Until recently, the treatment of TAO has most often proceeded as a treatment for pe-
ripheral arterial disease rather than vasculitis. TAO patients usually undergo angiography
to determine if they are eligible for angioplasty or bypass surgery, whilst the long-term
outcomes of such procedures are unfavourable. At the same time, the outcomes of TAO
patients who receive immunosuppressant medications, as in other types of vasculitis, are
highly variable and typically unfavourable.
In this review, we noted both similarities and differences between TAO and atheroscle-
rosis or vasculitis. These differences indicate that TAO is a disease entity distinct from
peripheral arterial disease or vasculitis. In addition, the common biomarkers showed
several common mechanisms in the development of TAO.
The tendency towards indistinctness regarding TAO may arise from the reductionism
methodology favoured by researchers and the mechanistic thinking employed in the study
of this disease. In addition, researchers tend to break down TAO into separate parts and
topics for study without considering the aggregate interconnectedness of the disease as
a whole. It is, after all, easy to lose sight of the whole when we focus our attention on
individual parts. Achieving a holistic view of TAO instead of focusing on its dissimilarities
to ASO or vasculitis can result in seeing the commonalities between TAO and other vascular
diseases for a better understanding of this disease.
Author Contributions: Conceptualization, B.F., D.L., and F.M.; data curation, S.K., R.M., and H.S.;
writing—original draft preparation, B.F., D.L., S.K., and H.S.; writing—review and editing, B.F., D.L.,
H.S., and F.M.; visualization of tables, B.F., D.L., R.M., S.K., and H.S.; revision and editing of tables,
B.F., D.L., S.K., and H.S.; supervision, F.M. All authors have read and agreed to the published version
of the manuscript.
Funding: This research received no external funding.
Diagnostics 2021, 11, 1736 15 of 20
Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.
Conflicts of Interest: The authors declare no conflict of interest.
References
1. Fazeli, B.; Rezaee, S.A. A review on Thromboangiitis obliterans pathophysiology: Thrombosis and angiitis, which is to blame?
Vascular 2011, 19, 141–153. [CrossRef] [PubMed]
2. Mills, J.L., Sr. Buerger’s disease in the 21st century: Diagnosis, clinical features, and therapy. In Seminars in Vascular Surgery; WB
Saunders: Philadelphia, PA, USA, 2003; Volume 16, pp. 179–189.
3. Joviliano, E.E.; Dellalibera-Joviliano, R.; Dalio, M.; Evora, P.R.; Piccinato, C.E. Etiopathogenesis, clinical diagnosis and treatment
of Thromboangiitis obliterans—Current practices. Int. J. Angiol. 2009, 18, 119–125. [CrossRef] [PubMed]
4. Shionoya, S. Diagnostic criteria of Buerger’s disease. Int. J. Cardiol. 1998, 66 (Suppl. S1), S243–S245. [CrossRef]
5. Fazeli, B. Buerger’s disease as an indicator of socioeconomic development in different societies, a cross-sectional descriptive
study in the North-East of Iran. Arch. Med. Sci. 2010, 6, 343–347. [CrossRef] [PubMed]
6. Fazeli, B.; Ravari, H. Hyperhomocysteinemia as a consequence of life style among patients suffering from Thromboangiitis
obliterans. Int. Angiol. 2013, 32, 442–443.
7. Zhou, J.; Austin, R.C. Contributions of hyperhomocysteinemia to atherosclerosis: Causal relationship and potential mechanisms.
Biofactors 2009, 35, 120–129. [CrossRef]
8. Jorge, V.C.; Araújo, A.C.; Noronha, C.; Panarra, A.; Riso, N.; Vaz Riscado, M. Buerger’s disease (Thromboangiitis obliterans): A
diagnostic challenge. BMJ Case Rep. 2011, 2011, bcr0820114621. [CrossRef] [PubMed]
9. Fazeli, B.; Ravari, H. A disease-specific activity score for Thromboangiitis obliterans. Vascular 2014, 22, 336–340. [CrossRef]
10. Akbarin, M.M.; Ravari, H.; Rajabnejad, A.; Valizadeh, N.; Fazeli, B. Investigation of the Etiology of Anemia in Thromboangiitis
Obliterans. Int. J. Angiol. 2016, 25, 153–158. [CrossRef]
11. Suresh, E. Diagnostic approach to patients with suspected vasculitis. Postgrad. Med. J. 2006, 82, 483–488. [CrossRef]
12. Kirkland, G.S.; Savige, J.; Wilson, D.; Heale, W.; Sinclair, R.A.; Hope, R.N. Classical polyarteritis nodosa and microscopic polyarteritis
with medium vessel involvement—A comparison of the clinical and laboratory features. Clin. Nephrol. 1997, 47, 176–180.
13. Pietraszek, M.H.; Choudhury, N.A.; Koyano, K.; Sakaguchi, S.; Kamiya, T.; Urano, T.; Takada, Y.; Takada, A. Enhanced platelet
response to serotonin in Buerger’s disease. Thromb Res. 1990, 60, 241–246. [CrossRef]
14. Keramat, S.; Sadeghian, M.H.; Keramati, M.R.; Fazeli, B. Assessment of T helper 17-associated cytokines in thromboangiitis
obliterans. J. Inflamm. Res. 2019, 12, 251–258. [CrossRef]
15. Murat, S.N.; Duran, M.; Kalay, N.; Gunebakmaz, O.; Akpek, M.; Doger, C.; Elcik, D.; Ocak, A.; Vatankulu, M.A.; Turfan, M.; et al.
Relation between mean platelet volume and severity of atherosclerosis in patients with acute coronary syndromes. Angiology
2013, 64, 131–136. [CrossRef]
16. Ataş, H.; Canpolat, F.; Eskioglu, F. Evaluation of Mean Platelet Volume in Patients with Behcet’s Disease as an Indicator of
Vascular Thrombosis. Arch. Iran Med. 2018, 21, 234–239. [PubMed]
17. Khan, A.; Haider, I.; Ayub, M.; Khan, S. Mean Platelet Volume (MPV) as an indicator of disease activity and severity in lupus.
F1000Res. 2017, 6, 126. [CrossRef]
18. Wessler, S. Thromboangiitis obliterans: Fact or fancy. Circulation 1961, 23, 165–167. [CrossRef] [PubMed]
19. Prusik, B.; Reinis, Z. Does Buerger’s disease exist? Angiologica 1964, 1, 94–102. [CrossRef]
20. Jain, R.B.; Ducatman, A. Associations between smoking and lipid/lipoprotein concentrations among US adults aged ≥20 years. J.
Circ. Biomark. 2018, 7, 1849454418779310. [CrossRef] [PubMed]
21. Hus, I.; Sokolowska, B.; Walter-Croneck, A.; Chrapko, M.; Nowaczynska, A.; Dmoszynska, A. Assessment of plasma prothrom-
botic factors in patients with Buerger’s disease. Blood Coagul. Fibrinolysis 2013, 24, 133–139. [CrossRef] [PubMed]
22. Ramin, M.; Salimi, J.; Meysamie, A. An Iranian scoring system for diagnosing Buerger’s disease. Acta Med. Iran 2014, 52, 60–65.
23. Hewing, B.; Stangl, V.; Stangl, K.; Enke-Melzer, K.; Baumann, G.; Ludwig, A. Circulating angiogenic factors in patients with
Thromboangiitis obliterans. PLoS ONE 2012, 7, e34717. [CrossRef] [PubMed]
24. Collens, W.S.; Wilensky, N.D. Thromboangiitis obliterans in a diabetic. Am. Heart J. 1939, 17, 624–627. [CrossRef]
25. Helm, S.; Horton, B. Thrombo-angiitis obliterans associated with diabetes mellitus. Ann. Intern. Med. 1939, 12, 1493–1498.
26. Papa, M.Z.; Adar, R. A Critical Look at Thromboangiitis Obliterans (Buerger’s disease). Perspect. Vasc. Surg. Endovasc. Ther. 1992,
5, 1–18. [CrossRef]
27. Igari, K.; Kudo, T.; Toyofuku, T.; Inoue, Y. Endothelial dysfunction in patients with Buerger disease. Vasc. Health Risk Manag. 2017,
13, 317–323. [CrossRef] [PubMed]
28. Fujii, Y.; Ohmura, Y.; Takeuchi, R.; Morimoto, S.; Uchida, H.; Hayashi, K.; Sano, S. Buerger’s disease in a middle-aged woman
with diabetes mellitus. A case report. Angiology 1996, 47, 97–102. [CrossRef] [PubMed]
29. Zannini, G.; Cotrufo, M. Epidemiological, angiographic and clinical aspects of Buerger’s disease. J. Cardiovasc. Surg. 1973, 14, 17–20.
30. Sena, C.M.; Leandro, A.; Azul, L.; Seiça, R.; Perry, G. Vascular Oxidative Stress: Impact and Therapeutic Approaches. Front.
Physiol. 2018, 9, 1668. [CrossRef]
Diagnostics 2021, 11, 1736 16 of 20
31. Marchio, P.; Guerra-Ojeda, S.; Vila, J.M.; Aldasoro, M.; Victor, V.M.; Mauricio, M.D. Targeting Early Atherosclerosis: A Focus on
Oxidative Stress and Inflammation. Oxid. Med. Cell Longev. 2019, 2019, 8563845. [CrossRef]
32. Senoner, T.; Dichtl, W. Oxidative Stress in Cardiovascular Diseases: Still a Therapeutic Target? Nutrients 2019, 11, 2090. [CrossRef]
33. Ito, F.; Sono, Y.; Ito, T. Measurement and Clinical Significance of Lipid Peroxidation as a Biomarker of Oxidative Stress: Oxidative
Stress in Diabetes, Atherosclerosis, and Chronic Inflammation. Antioxidants 2019, 8, 72. [CrossRef]
34. Alamdari, D.H.; Ravarit, H.; Tavallaie, S.; Fazeli, B. Oxidative and antioxidative pathways might contribute to Thromboangiitis
obliterans pathophysiology. Vascular 2014, 22, 46–50. [CrossRef]
35. Sharebiani, H.; Fazeli, B.; Maniscalco, R.; Ligi, D.; Mannello, F. The Imbalance among Oxidative Biomarkers and Antioxidant
Defense Systems in Thromboangiitis Obliterans (Winiwarter-Buerger Disease). J. Clin. Med. 2020, 9, 1036. [CrossRef] [PubMed]
36. Masoudian, M.; Fazeli, B.; Sharebiani, H.; Rajabnejad, A.; Ravari, H.; Akbarin, M.M.; Dadgarmoghaddam, M. Association of the
five gene related endothelial cell dysfunction polymorphisms with Buerger’s disease development. Int. Angiol. 2016, 35, 205–211.
[PubMed]
37. Muñoz-Sánchez, J.; Chánez-Cárdenas, M.E. A review on hemeoxygenase-2: Focus on cellular protection and oxygen response.
Oxid Med Cell Longev. 2014, 2014, 604981. [CrossRef] [PubMed]
38. Cziráki, A.; Lenkey, Z.; Sulyok, E.; Szokodi, I.; Koller, A. L-Arginine-Nitric Oxide-Asymmetric Dimethylarginine Pathway and
the Coronary Circulation: Translation of Basic Science Results to Clinical Practice. Front. Pharmacol. 2020, 11, 569914. [CrossRef]
39. Yeo, J.; Lee, Y.M.; Lee, J.; Park, D.; Kim, K.; Kim, J.; Park, J.; Kim, W.J. Nitric Oxide-Scavenging Nanogel for Treating Rheumatoid
Arthritis. Nano Lett. 2019, 19, 6716–6724. [CrossRef]
40. Pan, L.; Yang, S.; Wang, J.; Xu, M.; Wang, S.; Yi, H. Inducible nitric oxide synthase and systemic lupus erythematosus: A systematic
review and meta-analysis. BMC Immunol. 2020, 21, 10. [CrossRef]
41. İşcan, Y.; Yiğit, U.; Tuğcu, B.; Erdoğan, M.; Erdoğan, D.A.; Öner, V.; Taş, M.; Özyazgan, Y. Tear nitric oxide levels in Behçet’s
disease. Medicina 2012, 48, 559–562. [CrossRef]
42. da Silva, R.F.; Trapé, Á.A.; Reia, T.A.; Lacchini, R.; Oliveira-Paula, G.H.; Pinheiro, L.C.; Tanus-Santos, J.E.; Jacomini, A.M.; Bueno
Júnior, C.R.; Zago, A.S. Association of endothelial nitric oxide synthase (eNOS) gene polymorphisms and physical fitness levels
with plasma nitrite concentrations and arterial blood pressure values in older adults. PLoS ONE 2018, 13, e0206254. [CrossRef]
43. Lee, B.J.; Lin, Y.C.; Huang, Y.C.; Ko, Y.W.; Hsia, S.; Lin, P.T. The relationship between coenzyme Q10, oxidative stress, and
antioxidant enzymes activities and coronary artery disease. Sci. World J. 2012, 2012, 792756. [CrossRef] [PubMed]
44. Christensen, L.L.; Selman, C.; Blount, J.D.; Pilkington, J.G.; Watt, K.A.; Pemberton, J.M.; Reid, J.M.; Nussey, D.H. Plasma markers
of oxidative stress are uncorrelated in a wild mammal. Ecol. Evol. 2015, 5, 5096–5108. [CrossRef] [PubMed]
45. Peluso, I.; Palmery, M.; Drummen, G. Biomarkers of Oxidative Stress in Experimental Models and Human Studies with
Nutraceuticals: Measurement, Interpretation, and Significance 2017. Oxid. Med. Cell Longev. 2017, 2017, 3457917. [CrossRef]
[PubMed]
46. Arslan, C.; Altan, H.; Besirli, K.; Aydemir, B.; Kiziler, A.R.; Denli, S. The role of oxidative stress and antioxidant defenses in
Buerger disease and atherosclerotic peripheral arterial occlusive disease. Ann. Vasc. Surg. 2010, 24, 455–460. [CrossRef] [PubMed]
47. Shruthi, S.; Thabah, M.M.; Zachariah, B.; Negi, V.S. Association of Oxidative Stress with Disease Activity and Damage in Systemic
Lupus Erythematosus: A Cross Sectional Study from a Tertiary Care Centre in Southern India. Indian J. Clin. Biochem. 2021, 36,
185–193. [CrossRef] [PubMed]
48. Sam, N.B.; Li, B.Z.; Leng, R.X.; Pan, H.F.; Ye, D.Q. Circulating antioxidant levels in systemic lupus erythematosus patients: A
systematic review and meta-analysis. Biomark. Med. 2019, 13, 1137–1152. [CrossRef]
49. Song, Y.R.; Kim, J.K.; Lee, H.S.; Kim, S.G.; Choi, E.K. Serum levels of protein carbonyl, a marker of oxidative stress, are associated
with overhydration, sarcopenia and mortality in hemodialysis patients. BMC Nephrol. 2020, 21, 1–11. [CrossRef]
50. Shah, D.; Mahajan, N.; Sah, S.; Nath, S.K.; Paudyal, B. Oxidative stress and its biomarkers in systemic lupus erythematosus. J
Biomed Sci. 2014, 21, 1–13. [CrossRef] [PubMed]
51. Zuzak, E.; Horecka, A.; Kiełczykowska, M.; Dudek, A.; Musik, I.; Kurzepa, J.; Kurzepa, J. Glutathione level and glutathione
reductase activity in serum of coronary heart disease patients. J. Preclin. Clin. Res. 2017, 11, 103–105. [CrossRef]
52. Shah, D.; Sah, S.; Nath, S.K. Interaction between glutathione and apoptosis in systemic lupus erythematosus. Autoimmun. Rev.
2013, 12, 741–751. [CrossRef] [PubMed]
53. Senders, M.L.; Mulder, W.J.M. Targeting myeloperoxidase in inflammatory atherosclerosis. Eur Heart J 2018, 39, 3311–3313.
[CrossRef] [PubMed]
54. Emmi, G.; Becatti, M.; Bettiol, A.; Hatemi, G.; Prisco, D.; Fiorillo, C. Behçet’s Syndrome as a Model of Thrombo-Inflammation:
The Role of Neutrophils. Front. Immunol. 2019, 10, 1085. [CrossRef] [PubMed]
55. Suárez-Rivero, J.M.; Pastor-Maldonado, C.J.; de la Mata, M.; Villanueva-Paz, M.; Povea-Cabello, S.; Álvarez-Córdoba, M.;
Villalón-García, I.; Suárez-Carrillo, A.; Talaverón-Rey, M.; Munuera, M.; et al. Atherosclerosis and Coenzyme Q (10). Int. J. Mol.
Sci. 2019, 20, 5195. [CrossRef]
56. Su, Y.J.; Cheng, T.T.; Chen, C.J.; Chiu, W.C.; Chang, W.N.; Tsai, N.W.; Kung, C.T.; Lin, W.C.; Huang, C.C.; Chang, Y.T.; et al. The
association among antioxidant enzymes, autoantibodies, and disease severity score in systemic lupus erythematosus: Comparison
of neuropsychiatric and nonneuropsychiatric groups. BioMed Res. Int. 2014, 2014, 137231. [CrossRef]
57. Cerne, D.; Kaplan-Pavlovcic, S.; Kranjec, I.; Jurgens, G. Mildly elevated serum creatinine concentration correlates with the extent
of coronary atherosclerosis. Ren. Fail. 2000, 22, 799–808. [CrossRef]
Diagnostics 2021, 11, 1736 17 of 20
58. Yun, H.J.; Kim, D.I.; Lee, K.H.; Lim, S.J.; Hwang, W.M.; Yun, S.R.; Yoon, S.H. End stage renal disease caused by Thromboangiitis
obliterans: A case report. J. Med. Case Rep. 2015, 9, 1–5. [CrossRef]
59. Shi, J.; Shen, Q.; Chen, X.M.; Du, X.G. Clinical characteristics and outcomes in microscopic polyangiitis patients with renal
involvement: A study of 124 Chinese patients. BMC Nephrol. 2019, 20, 1–10. [CrossRef]
60. Roncon-Albuquerque, R.; Serrão, P.; Vale-Pereira, R.; Costa-Lima, J.; Roncon-Albuquerque, R., Jr. Plasma catecholamines in
Buerger’s disease: Effects of cigarette smoking and surgical sympathectomy. Eur. J. Vasc. Endovasc. Surg. 2002, 24, 338–343.
[CrossRef]
61. Bauch, H.J.; Grünwald, J.; Vischer, P.; Gerlach, U.; Hauss, W.H. A possible role of catecholamines in atherogenesis and subsequent
complications of atherosclerosis. Exp. Pathol. 1987, 31, 193–204. [CrossRef]
62. Sarathi, V.; Lila, A.R.; Bandgar, T.R.; Shah, N.S. Aortoarteritis: Could it be a form of catecholamine-induced vasculitis? Indian J.
Endocrinol. Metab. 2013, 17, 163–166. [CrossRef]
63. Toutai, C.; Berrajaa, M.; Aissaoui, H.; Elouafi, N.; Jabi, R.; Bouziane, M.; Latrech, H.; Housni, B.; Ismaili, N. Rare association of
aortoarteritis and pheochromocytoma: A case report. Int. J. Surg. Case Rep. 2020, 77, 91–95. [CrossRef]
64. Ali, H.; Khan, E.; Ilahi, I. Environmental Chemistry and Ecotoxicology of Hazardous Heavy Metals: Environmental Persistence,
Toxicity, and Bioaccumulation. J. Chem. 2019, 2019, 6730305. [CrossRef]
65. Patwa, J.; Flora, S.J.S. Heavy Metal-Induced Cerebral Small Vessel Disease: Insights into Molecular Mechanisms and Possible
Reversal Strategies. Int. J. Mol. Sci. 2020, 21, 3862. [CrossRef] [PubMed]
66. Mousazadeh, B.; Sharebiani, H.; Taheri, H.; Valizedeh, N.; Fazeli, B. Unexpected inflammation in the sympathetic ganglia in
Thromboangiitis obliterans: More likely sterile or infectious induced inflammation? Clin. Mol. Allergy 2019, 17, 1–7. [CrossRef]
[PubMed]
67. Harari, F.; Barregard, L.; Östling, G.; Sallsten, G.; Hedblad, B.; Forsgard, N.; Borné, Y.; Fagerberg, B.; Engström, G. Blood Lead
Levels and Risk of Atherosclerosis in the Carotid Artery: Results from a Swedish Cohort. Environ. Health Perspect. 2019, 127,
127002. [CrossRef]
68. Tinkov, A.A.; Filippini, T.; Ajsuvakova, O.P.; Skalnaya, M.G.; Aaseth, J.; Bjørklund, G.; Gatiatulina, E.R.; Popova, E.V.; Ne-
mereshina, O.N.; Huang, P.T.; et al. cadmium and atherosclerosis: A review of toxicological mechanisms and a meta-analysis of
epidemiologic studies. Environ. Res. 2018, 162, 240–260. [CrossRef] [PubMed]
69. Alba, M.A.; Jennette, J.C.; Falk, R.J. Pathogenesis of ANCA-Associated Pulmonary Vasculitis. Semin. Respir. Crit. Care Med. 2018,
70. Albert, D.; Clarkin, C.; Komoroski, J.; Brensinger, C.M.; Berlin, J.A. Wegener’s granulomatosis: Possible role of environmental
agents in its pathogenesis. Arthritis Rheum. 2004, 51, 656–664. [CrossRef] [PubMed]
71. Metryka, E.; Chibowska, K.; Gutowska, I.; Falkowska, A.; Kupnicka, P.; Barczak, K.; Chlubek, D.; Baranowska-Bosiacka, I. Lead
(Pb) Exposure Enhances Expression of Factors Associated with Inflammation. Int. J. Mol. Sci. 2018, 19, 1813. [CrossRef] [PubMed]
72. Bulmer, A.C.; Bakrania, B.; Du Toit, E.F.; Boon, A.C.; Clark, P.J.; Powell, L.W.; Wagner, K.H.; Headrick, J.P. Bilirubin acts as a
multipotent guardian of cardiovascular integrity: More than just a radical idea. Am. J. Physiol. Heart Circ. Physiol. 2018, 315,
H429–H447. [CrossRef] [PubMed]
73. Schwertner, H.A.; Jackson, W.G.; Tolan, G. Association of low serum concentration of bilirubin with increased risk of coronary
artery disease. Clin. Chem. 1994, 40, 18–23. [CrossRef] [PubMed]
74. Suh, S.; Cho, Y.R.; Park, M.K.; Kim, D.K.; Cho, N.H.; Lee, M.K. Relationship between serum bilirubin levels and cardiovascular
disease. PLoS ONE 2018, 13, e0193041. [CrossRef] [PubMed]
75. Chen, W.Q.; Dai, X.N.; Yu, Y.; Wang, Q.; Liang, J.Y.; Ke, Y.N.; Yi, C.H.; Lin, J. Analysis of clinical features and prognosis in patients
with primary Sjögren’s syndrome and autoimmune liver disease. J. Peking Univ. Health Sci. 2020, 52, 886–891.
76. Jäger, U.; Barcellini, W.; Broome, C.M.; Gertz, M.A.; Hill, A.; Hill, Q.A.; Jilma, B.; Kuter, D.J.; Michel, M.; Montillo, M.; et al.
Diagnosis and treatment of autoimmune hemolytic anemia in adults: Recommendations from the First International Consensus
Meeting. Blood Rev. 2020, 41, 100648. [CrossRef] [PubMed]
77. Tovoli, F.; Vannini, A.; Fusconi, M.; Frisoni, M.; Zauli, D. Autoimmune liver disorders and small-vessel vasculitis: Four case
reports and review of the literature. Ann Hepatol. 2013, 13, 136–141. [CrossRef]
78. Koca, T.T. Clinical Significance of Serum Bilirubin in Behçet’s Disease. J. Transl. Int. Med. 2018, 6, 185–188. [CrossRef] [PubMed]
79. Goh, G.B.; Pagadala, M.R.; Dasarathy, J.; Unalp-Arida, A.; Pai, R.K.; Yerian, L.; Khiyami, A.; Sourianarayanane, A.; Sargent, R.;
Hawkins, C.; et al. Age impacts ability of aspartate-alanine aminotransferase ratio to predict advanced fibrosis in nonalcoholic
Fatty liver disease. Dig. Dis. Sci. 2015, 60, 1825–1831. [CrossRef]
80. Lonardo, A.; Ballestri, S.; Guaraldi, G.; Nascimbeni, F.; Romagnoli, D.; Zona, S.; Targher, G. Fatty liver is associated with an
increased risk of diabetes and cardiovascular disease—Evidence from three different disease models: NAFLD, HCV and HIV.
World J. Gastroenterol. 2016, 22, 9674–9693. [CrossRef]
81. Olin, J.W. Thromboangiitis obliterans (Buerger’s disease). New Engl. J. Med. 2000, 343, 864–869. [CrossRef]
82. Vijayakumar, A.; Tiwari, R.; Kumar Prabhuswamy, V. Thromboangiitis obliterans (Buerger’s disease)-Current Practices. Int. J.
Inflam. 2013, 2013, 156905. [CrossRef] [PubMed]
83. Dellalibera-Joviliano, R.; Joviliano, E.E.; Silva, J.S.; Evora, P.R. Activation of cytokines corroborate with development of inflamma-
tion and autoimmunity in Thromboangiitis obliterans patients. Clin. Exp. Immunol. 2012, 170, 28–35. [CrossRef]
Diagnostics 2021, 11, 1736 18 of 20
84. Wu, S.; Sun, X.; Wu, W.; Shi, D.; Jiang, T. Effect of revascularization on IL-6 and TNF-α in patients with Thromboangiitis obliterans.
Exp. Ther. Med. 2018, 15, 3947–3951. [CrossRef] [PubMed]
85. Joras, M.; Poredos, P.; Fras, Z. Endothelial dysfunction in Buerger’s disease and its relation to markers of inflammation. Eur. J.
Clin. Invest. 2006, 36, 376–382. [CrossRef]
86. Slavov, E.S.; Stanilova, S.A.; Petkov, D.P.; Dobreva, Z.G. Cytokine production in Thromboangiitis obliterans patients: New
evidence for an immune-mediated inflammatory disorder. Clin. Exp. Rheumatol. 2005, 23, 219–226.
87. Sharebiani, H.; Mohareri, M.; Mirhosseini, A.; Fazeli, B. The IL-33/sST2 Axis in Thromboangiitis obliterans. J. Inflamm. Res. 2020,
88. Shapouri-Moghaddam, A.; Mohammadi, M.; Rahimi, H.R.; Esmaeili, H.; Mahmoudi, M.; Saeed Modaghegh, M.H.; Tavakol
Afshari, J. The Association of HLA-A, B and DRB1 with Buerger’s disease. Rep. Biochem. Mol. Biol. 2019, 8, 153–160. [PubMed]
89. Fehérvári, M.; Krepuska, M.; Széplaki, G.; Apor, A.; Sótonyi, P.; Prohászka, Z.; Acsády, G.; Szeberin, Z. The level of complement
C3 is associated with the severity of atherosclerosis but not with arterial calcification in peripheral artery disease. Int. Angiol.
2014, 33, 35–41.
90. Omoyinmi, E.; Mohamoud, I.; Gilmour, K.; Brogan, P.A.; Eleftheriou, D. Cutaneous Vasculitis and Digital Ischaemia Caused by
Heterozygous Gain-of-Function Mutation in C3. Front. Immunol. 2018, 9, 2524. [CrossRef]
91. Augusto, J.F.; Langs, V.; Demiselle, J.; Lavigne, C.; Brilland, B.; Duveau, A.; Poli, C.; Chevailler, A.; Croue, A.; Tollis, F.; et al. Low
Serum Complement C3 Levels at Diagnosis of Renal ANCA-Associated Vasculitis Is Associated with Poor Prognosis. PLoS ONE
2016, 11, e0158871.
92. Mohareri, M.; Mirhosseini, A.; Mehraban, S.; Fazeli, B. Thromboangiitis obliterans episode: Autoimmune flare-up or reinfection?
Vasc. Health Risk Manag. 2018, 14, 247–251. [CrossRef]
93. De Caridi, G.; Bitto, A.; Massara, M.; Pallio, G.; Pizzino, G.; Serra, R.; Altavilla, D.; Squadrito, F.; Spinelli, F. Increased Serum
HMGB-1, ICAM-1 and Metalloproteinase-9 Levels in Buerger’s Patients. Curr. Vasc. Pharmacol. 2016, 14, 382–387. [CrossRef]
94. Fazeli, B.; Rafatpanah, H.; Ravari, H.; Farid Hosseini, R.; Tavakol Afshari, J.; Hamidi Alamdari, D.; Valizadeh, N.; Moheghi,
N.; Rezaee, S.A. Sera of patients with Thromboangiitis obliterans activated cultured human umbilical vein endothelial cells
(HUVECs) and changed their adhesive properties. Int. J. Rheum. Dis. 2014, 17, 106–112. [CrossRef]
95. Wei, Z.; Jiang, W.; Wang, H.; Li, H.; Tang, B.; Liu, B.; Jiang, H.; Sun, X. The IL-6/STAT3 pathway regulates adhesion molecules
and cytoskeleton of endothelial cells in Thromboangiitis obliterans. Cell. Signal. 2018, 44, 118–126. [CrossRef]
96. Olejarz, W.; Łacheta, D.; Kubiak-Tomaszewska, G. Matrix Metalloproteinases as Biomarkers of Atherosclerotic Plaque Instability.
Int. J. Mol. Sci. 2020, 21, 3946. [CrossRef]
97. Pay, S.; Abbasov, T.; Erdem, H.; Musabak, U.; Simsek, I.; Pekel, A.; Akdogan, A.; Sengul, A.; Dinc, A. Serum MMP-2 and MMP-9
in patients with Behçet’s disease: Do their higher levels correlate to vasculo-Behçet’s disease associated with aneurysm formation?
Clin. Exp. Rheumatol. 2007, 25, S70–S75.
98. Monach, P.A.; Warner, R.L.; Tomasson, G.; Specks, U.; Stone, J.H.; Ding, L.; Fervenza, F.C.; Fessler, B.J.; Hoffman, G.S.; Iklé, D.;
et al. Serum proteins reflecting inflammation, injury and repair as biomarkers of disease activity in ANCA-associated vasculitis.
Ann. Rheum. Dis. 2013, 72, 1342–1350. [CrossRef]
99. Piazza, G.; Creager, M.A. Thromboangiitis obliterans. Circulation 2010, 121, 1858–1861. [CrossRef]
100. Shapouri-Moghaddam, A.; Saeed Modaghegh, M.H.; Rahimi, H.R.; Ehteshamfar, S.M.; Tavakol Afshari, J. Molecular mechanisms
regulating immune responses in Thromboangiitis obliterans: A comprehensive review. Iran J. Basic Med. Sci 2019, 22, 215–224.
[PubMed]
101. Ketha, S.S.; Cooper, L.T. The role of autoimmunity in Thromboangiitis obliterans (Buerger’s disease). Ann. N. Y. Acad. Sci. 2013,
1285, 15–25. [CrossRef]
102. Berlit, P.; Kessler, C.; Reuther, R.; Krause, K.H. New aspects of Thromboangiitis obliterans (von Winiwarter-Buerger’s disease).
Eur. Neurol. 1984, 23, 394–399. [CrossRef] [PubMed]
103. Halacheva, K.S.; Manolova, I.M.; Petkov, D.P.; Andreev, A.P. Study of anti-neutrophil cytoplasmic antibodies in patients with
Thromboangiitis obliterans (Buerger’s disease). Scand. J. Immunol. 1998, 48, 544–550.
104. Guo, Y.; Dai, Y.; Lai, J.; Fan, Y. Study about correlation of anti-neutrophil cytoplasmic antibodies and anticardiolipin antibodies
with Thromboangiitis obliterans. Vascular 2013, 21, 363–368. [CrossRef]
105. Iwai, T.; Umeda, M.; Inoue, Y.; Dental University Buerger Disease Research Group. Pathogenic Mechanism of the Artery and the
Vein in Buerger Disease: Our Hypothesis. Angiology 2014, 2, 1–4.
106. Chavoshan, A.; Sharebiani, H.; Taheri, H.; Fazeli, B. Antiphospholipid antibodies in Buerger’s disease. Thromb. Res. 2019, 181,
64–66. [CrossRef]
107. Zhao, X.; Wen, Q.; Qiu, Y.; Huang, F. Clinical and pathological characteristics of ANA/anti-dsDNA positive patients with
antineutrophil cytoplasmic autoantibody-associated vasculitis. Rheumatol. Int. 2021, 41, 455–462. [CrossRef]
108. Dinckal, M.H.; Ozkaynak, B.; Mert, B.; Sahin, I.; Sigirci, S.; Gulsen, K.; Ayca, B.; Okuyan, E. The relationship between antibeta 2
glycoprotein antibodies and SYNTAX score in patients undergoing coronary artery bypass graft surgery. Eur. Rev. Med. Pharmacol.
Sci. 2014, 18, 2556–2561. [PubMed]
109. Legendre, P.; Régent, A.; Thiebault, M.; Mouthon, L. Anti-endothelial cell antibodies in vasculitis: A systematic review. Autoimmun.
Rev. 2017, 16, 146–153. [CrossRef] [PubMed]
Diagnostics 2021, 11, 1736 19 of 20
110. Loeffen, R.; Spronk, H.M.; ten Cate, H. The impact of blood coagulability on atherosclerosis and cardiovascular disease. J. Thromb.
Haemost. 2012, 10, 1207–1216. [CrossRef]
111. Undas, A.; Nowakowski, T.; Cieśla-Dul, M.; Sadowski, J. Abnormal plasma fibrin clot characteristics are associated with worse
clinical outcome in patients with peripheral arterial disease and Thromboangiitis obliterans. Atherosclerosis 2011, 215, 481–486.
[CrossRef]
112. Rivera-Chavarría, I.J.; Brenes-Gutiérrez, J.D. Thromboangiitis obliterans (Buerger’s disease). Ann. Med. Surg. 2016, 7, 79–82.
[CrossRef]
113. Raymackers, J.M.; Bosschaert, P. Cerebral venous thrombosis and Buerger’s disease. Acta Neurol. Belg. 2014, 114, 139–140.
[CrossRef] [PubMed]
114. Sato, T.; Tamai, H.; Kobayashi, M.; Yamamoto, K.; Komori, K. Immunohistochemical properties in the patients with Buerger’s
disease–possible role of plasminogen activator inhibitor-1 for preservation of vessel wall architecture. Cardiovasc. Pathol. 2011, 20,
266–271. [CrossRef]
115. Emmanuel, A.; Selvaraj, D.; Sen, I.; Agarwal, S.; Stephen, E.; Kota, A.; Nair, S.C.; Antoniswamy, B. D-dimer levels in patients with
Thromboangiitis obliterans. Natl. Med. J. India 2019, 32, 134–136. [CrossRef] [PubMed]
116. Mensa, M.; Dobbs, T.; Jessop, Z.M.; Whitaker, I.S. Homozygous Factor V Leiden Thrombophilia in a Patient with Histologically
Confirmed Thromboangiitis obliterans. Clin. Med. Insights Case Rep. 2019, 12, 1179547619828719. [CrossRef]
117. Avcu, F.; Akar, E.; Demirkiliç, U.; Yilmaz, E.; Akar, N.; Yalçin, A. The role of prothrombotic mutations in patients with Buerger’s
disease. Thromb. Res. 2000, 100, 143–147. [CrossRef]
118. Beigi, A.A.; Hoghoughi, M.A.; Eshaghian, A.; Zade, A.H.; Masoudpour, H. The role of folic acid on the hyperhomocysteinemia in
the Buerger’s disease (Thromboangiitis obliterans). J. Res. Med. Sci. 2014, 19, 1034–1037.
119. Barroso, M.; Handy, D.E.; Castro, R. The Link Between Hyperhomocysteinemia and Hypomethylation: Implications for Cardio-
vascular Disease. J. Inborn Errors Metab. Screen. 2017, 5, 2326409817698994. [CrossRef]
120. Stammler, F.; Diehm, C.; Hsu, E.; Stockinger, K.; Amendt, K. The prevalence of hyperhomocysteinemia in Thromboangiitis
obliterans. Does homocysteine play a role pathogenetically? Dtsch. Med. Wochenschr. 1996, 121, 1417–1423. [CrossRef]
121. Birch, C.A. Buerger’s disease. Leo Buerger (1879–1943). Practitioner 1973, 211, 823–824.
122. Gantcheva, M. The Significance of Anticardiolipin Antibodies in Patients with Vasculitis. Acta Morphol. et Anthropol. 2018, 25, 38–43.
123. Batu, E.D. Neutrophil-mediated Thrombosis and NETosis in Behçet’s Disease: A Hypothesis. J. Korean Med. Sci. 2020, 35, e213.
[CrossRef] [PubMed]
124. Borowiec, A.; Dabrowski,
˛ R.; Kowalik, I.; Rusinowicz, T.; Hadzik-Błaszczyk, M.; Krupa, R.; Życińska, K. Elevated levels of
d-dimer are associated with inflammation and disease activity rather than risk of venous thromboembolism in patients with
granulomatosis with polyangiitis in long term observation. Adv. Med. Sci. 2020, 65, 97–101. [CrossRef]
125. Piazzolla, G.; Candigliota, M.; Fanelli, M.; Castrovilli, A.; Berardi, E.; Antonica, G.; Battaglia, S.; Solfrizzi, V.; Sabbà, C.; Tortorella,
C. Hyperhomocysteinemia is an independent risk factor of atherosclerosis in patients with metabolic syndrome. Diabetol. Metab.
Syndr. 2019, 11, 1–9. [CrossRef] [PubMed]
126. Hamzaoui, A.; Harzallah, O.; Klii, R.; Mahjoub, S. Hyperhomocysteinaemia in Behçet’s Disease. Biochem. Res. Int. 2010, 2010,
361387. [CrossRef] [PubMed]
127. Buerger, L. Is thromboangiitis an infectious disease? Surg. Gynecol. Obstet. 1914, 19, 582–588.
128. Iwai, T.; Inoue, Y.; Umeda, M.; Huang, Y.; Kurihara, N.; Koike, M.; Ishikawa, I. Oral bacteria in the occluded arteries of patients
with Buerger disease. J. Vasc. Surg. 2005, 42, 107–115. [CrossRef]
129. Fazeli, B.; Mirhosseini, A.; Hashemi, Z.; Taheri, H. Detection of Rickettsia Endosymbiont Bemisia Tabaci in the Amputated Limbs
of Three Buerger’s disease Patients. Int. Med. Case Rep. J. 2020, 13, 33–40. [CrossRef]
130. Li, B.; Xia, Y.; Hu, B. Infection and atherosclerosis: TLR-dependent pathways. Cell. Mol. Life. Sci. 2020, 77, 2751–2769. [CrossRef]
131. C, B.R. Sample size considerations in genetic polymorphism studies. Hum. Hered. 2001, 52, 191–200.
132. McLoughlin, G.A.; Helsby, C.R.; Evans, C.C.; Chapman, D.M. Association of HLA-A9 and HLA-B5 with Buerger’s disease. Br.
Med. J. 1976, 2, 1165–1166. [CrossRef]
133. Aerbajinai, W.; Tsuchiya, T.; Kimura, A.; Yasukochi, Y.; Numano, F. HLA class II DNA typing in Buerger’s disease. Int. J. Cardiol.
1996, 54, S197–S202. [CrossRef]
134. Tiwari, J.L.; Terasaki, P.I. HLA-DR and disease associations. Prog. Clin. Biol. Res. 1981, 58, 151–163.
135. Jaini, R.; Mandal, S.; Khazanchi, R.K.; Mehra, N.K. Immunogenetic analysis of Buerger’s disease in India. Int. J. Cardiol. 1998, 66
(Suppl. S1), S283–S285. [CrossRef]
136. Numano, F.; Sasazuki, T.; Koyama, T.; Shimokado, K.; Takeda, Y.; Nishimura, Y.; Mutoh, M. HLA in Buerger’s disease. Exp. Clin.
Immunogenet. 1986, 3, 195–200.
137. Cao, Y.; Schmitz, J.L.; Yang, J.; Hogan, S.L.; Bunch, D.; Hu, Y.; Jennette, C.E.; Berg, E.A.; Arnett, F.C., Jr.; Jennette, J.C.; et al.
DRB1*15 allele is a risk factor for PR3-ANCA disease in African Americans. J. Am. Soc. Nephrol. 2011, 22, 1161–1167. [CrossRef]
138. Gonzalez-Gay, M.A.; Garcia-Porrua, C.; Hajeer, A.H.; Dababneh, A.; Ollier, W.E. HLA-DRB1*04 may be a marker of severity in
giant cell arteritis. Ann. Rheum. Dis. 2000, 59, 574–575. [CrossRef]
139. Voskuyl, A.E.; Hazes, J.M.; Schreuder, G.M.; Schipper, R.F.; de Vries, R.R.; Breedveld, F.C. HLA-DRB1, DQA1, and DQB1
genotypes and risk of vasculitis in patients with rheumatoid arthritis. J. Rheumatol. 1997, 24, 852–855.
Diagnostics 2021, 11, 1736 20 of 20
140. Gorman, J.D.; David-Vaudey, E.; Pai, M.; Lum, R.F.; Criswell, L.A. Particular HLA-DRB1 shared epitope genotypes are strongly
associated with rheumatoid vasculitis. Arthritis Rheum. 2004, 50, 3476–3484. [CrossRef]
141. Boechat Nde, O.; Ogusku, M.M.; Boechat, A.L.; Sadahiro, A. Interaction between smoking and HLA-DRB1*04 gene is associated
with a high cardiovascular risk in Brazilian Amazon patients with rheumatoid arthritis. PLoS ONE 2012, 7, e41588. [CrossRef]
[PubMed]
142. Glueck, C.J.; Haque, M.; Winarska, M.; Dharashivkar, S.; Fontaine, R.N.; Zhu, B.; Wang, P. Stromelysin-1 5A/6A and eNOS
T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: A pilot, hypothesis-generating
study of gene-environment pathophysiological associations with Buerger’s disease. Clin. Appl. Thromb. Hemost. 2006, 12, 427–439.
[CrossRef]
143. Cheng, Y.; Xiong, M.; Liu, Y.; Tang, B. Lack of association between endothelial nitric oxide synthase gene polymorphisms with
vasculitis: A meta-analysis. Clin. Exp. Rheumatol. 2015, 33, S107–S112.
144. Barbosa, A.M.; Silva, K.S.F.; Lagares, M.H.; Rodrigues, D.A.; da Costa, I.R.; Morais, M.P.; Martins, J.V.M.; Mascarenhas, R.S.;
Campedelli, F.L.; Moura, K. Atherosclerosis: Analysis of the eNOS (T786C) gene polymorphism. Genet. Mol. Res. 2017, 16,
gmr16039708. [CrossRef] [PubMed]
145. Kim, I.J.; Bae, J.; Lim, S.W.; Cha, D.H.; Cho, H.J.; Kim, S.; Yang, D.H.; Hwang, S.G.; Oh, D.; Kim, N.K. Influence of endothelial
nitric oxide synthase gene polymorphisms (-786T>C, 4a4b, 894G>T) in Korean patients with coronary artery disease. Thromb. Res.
2007, 119, 579–585. [CrossRef] [PubMed]
146. Pellegrino, D.; Sprovieri, E.; Mazza, R.; Randall, D.J.; Tota, B. Nitric oxide-cGMP-mediated vasoconstriction and effects of
acetylcholine in the branchial circulation of the eel. Comp. Biochem. Physiol. A Mol. Integr. Physiol. 2002, 132, 447–457. [CrossRef]
147. Cicchese, J.M.; Evans, S.; Hult, C.; Joslyn, L.R.; Wessler, T.; Millar, J.A.; Marino, S.; Cilfone, N.A.; Mattila, J.T.; Linderman, J.J.; et al.
Dynamic balance of pro- and anti-inflammatory signals controls disease and limits pathology. Immunol. Rev. 2018, 285, 147–167.
[CrossRef]
148. Fillatreau, S. B cells and their cytokine activities implications in human diseases. Clin Immunol 2018, 186, 26–31. [CrossRef]
149. Lee, T.; Seo, J.W.; Sumpio, B.E.; Kim, S.J. Immunobiologic analysis of arterial tissue in Buerger’s disease. Eur. J. Vasc. Endovasc.
Surg. 2003, 25, 451–457. [CrossRef]
150. Junuzovic, D.; Zunic, L.; Dervisefendic, M.; Skopljak, A.; Pasagic, A.; Masic, I. The toxic effect on leukocyte lineage of antimicrobial
therapy in urinary and respiratory infections. Med. Arh. 2014, 68, 167–169. [CrossRef] [PubMed]
151. Sarnak, M.J.; Tighiouart, H.; Manjunath, G.; MacLeod, B.; Griffith, J.; Salem, D.; Levey, A.S. Anemia as a risk factor for
cardiovascular disease in The Atherosclerosis Risk in Communities (ARIC) study. J. Am. Coll. Cardiol. 2002, 40, 27–33. [CrossRef]
152. Kawamura, T.; Usui, J.; Kaneko, S.; Tsunoda, R.; Imai, E.; Kai, H.; Morito, N.; Saito, C.; Nagata, M.; Yamagata, K. Anaemia is an
essential complication of ANCA-associated renal vasculitis: A single center cohort study. BMC Nephrol. 2017, 18, 1–8. [CrossRef]
[PubMed]
153. Hegg, R.; Lee, A.G.; Tagg, N.T.; Zimmerman, M.B. Statin or nonsteroidal anti-inflammatory drug use is associated with lower
erythrocyte sedimentation rate in patients with giant cell arteritis. J. Neuroophthalmol. 2011, 31, 135–138. [CrossRef] [PubMed]

Recent Updates and Advances in Winiwarter-Buerger

Uploaded by

Copyright:

Available Formats

Recent Updates and Advances in Winiwarter-Buerger

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Recent Updates and Advances in Winiwarter-Buerger

Uploaded by

Copyright:

Available Formats

diagnostics

Keywords: Buerger’s disease; Thromboangiitis obliterans; oxidative stress; antioxidant capacity;

Diagnostics 2021, 11, 1736. https://doi.org/10.3390/diagnostics11101736 https://www.mdpi.com/journal/diagnostics

2. Complete Blood Count (CBC)

Table 1. Summary of the main findings on Complete Blood Count (CBC).

CBC TAO Atherosclerosis Vasculitis

3.2. Blood Sugar

3.3. Oxidative Stress

3.5. Catecholamine Concentration

3.6. Heavy Metals

3.8. Liver Function Test

Table 2. Summary of the main findings on biochemical markers.

Biochemical Markers TAO Atherosclerosis Vasculitis

4.3. Complement Component

4.4. Other Inflammatory Mediators

Table 3. Summary of the main findings on inflammatory markers.

Inflammatory Biomarkers TAO Atherosclerosis Vasculitis

Table 4. Summary of the main findings on autoantibodies.

Autoantibodies TAO Atherosclerosis Vasculitis

A summary of the main findings is reported in Table 4.

Table 5. Summary of the main findings on thrombotic factors.

Thrombotic Factors TAO Atherosclerosis Vasculitis

Table 6. Summary of the main findings on infection.

TAO Atherosclerosis Vasculitis

No association between HLA-DRB1*15 and atherosclerosis has been reported. However,

9.1. Similar Biomarkers

9.2. Controversial Biomarkers

9.3. Differential Biomarkers

Institutional Review Board Statement: Not applicable.

You might also like